It is an honor to write the preface to this fascinating edition on *Key Leaders’ Opinion on Precision Medicine in Hepatobiliary Cancer*. The perspectives from many countries like China, USA, Germany, France, Italy, Spain and the rest of the world provide an easy and impressive introductory course to the diagnosis and treatment of liver cancer and gallbladder cancer. Most importantly, it allows us to further focus on the untapped potential of precision medicine in hepatobiliary cancer.

As one of the leading causes of cancer-related mortality worldwide in man and lack of consistent outcome for conventional therapies, liver cancer is a heterogeneous malignant disease which calls for immunotherapy and metabolism therapy in the future studies. As science and next-generation sequencing technologies advance, the molecular diagram has profoundly changed in recent years. However, the knowledge has lagged behind the technical improvements and the studies have not yet been fully applied into clinical practice.

The book divided into two sections of liver cancer and gallbladder cancer, covers a wide range of hot topics in precision medicine: hepatic epithelial transforming growth factor-β signaling, Vps4A-mediated tumor suppression, SETDB1, multi-omics strategy, decoding multifocal hepatocellular carcinoma, Sulfatase 1, STAT3, Chromodomain-helicase-DNA-binding protein 4, combination PARP and HDAC inhibition, hedgehog signaling pathway, etc. All these topics are thought-provoking and will help the clinicians to apply precision medicine in daily work in a personalized manner.

Drawing on the experience of international experts in the field, the edition is an extraordinary work and it is well worth a read for a comprehensive understanding of the field. There is no question that clinicians and healthcare professionals reading this book will benefit from its wisdom and gain the knowledge needed in providing the highest quality care to their patients.

**Xuehao Wang, MD**
Academician of the Chinese Academy of Engineering,
Liver Transplantation Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.